Over 900 life science industry executives expected at event next week
WASHINGTON & CARLSBAD, Calif. & BOSTON--(BUSINESS WIRE)--
The sixth annual international life science partnering event, BioPharm
America™ 2013, kicks off next week at the Westin
Boston Waterfront in Boston, MA. A total of 530 companies, including
innovative biotech, pharma and investors, are expected to converge upon
Boston for the three-day event held September 17–19.
This includes business development executives from Amgen, AstraZeneca,
Bayer, Biogen Idec, EMD Serono, Epizyme, GlaxoSmithKline, Janssen
Pharmaceutical Companies of Johnson & Johnson, Merck, Novo Nordisk, Onyx
Pharmaceuticals, Organogenesis, Pfizer, Sanofi, Shire Pharmaceuticals,
and Vertex, as well as venture capital firms including 5AM Ventures,
Aisling Capital, Atlas Capital, Forbion Capital Partners, Flagship
Ventures, Google Ventures, Index Ventures, PureTech Ventures, Rosetta
Capital Ltd., Skyline Ventures, SR One, Third Rock Ventures, Wildwood
Ventures, and more.
“BioPharm America continues to be the premier biotech and life science
partnering event in North America, bringing together pharma leaders from
the US and Europe, as well as from other leading global life science
regions,” said Florian Schoenhammer, Group Managing Director of
companies range from preclinical “next generation” companies to mid-
and late-stage biotech. A new Academic Innovators™ Showcase presentation
track, sponsored by Johnson & Johnson Innovation, will highlight
academic research with strong translational potential.